Skip to main content

Akari Therapeutics Plc

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

AKTX$7.66+3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(Amounts in thousands, except share and per share data)

June 30,December 31,
20262025
ASSETS
Current assets:
Cash$7,694$5,203
Restricted cash6060
Prepaid expenses532185
Other current assets3814
Total current assets8,3245,462
Goodwill—8,430
Other intangible assets30,30034,000
Total assets$38,624$47,892
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable$9,401$8,770
Accrued expenses3,5132,342
Convertible notes, net693673
Notes payable, net—81
Warrant liabilities11661
Other current liabilities212424
Total current liabilities13,93512,351
Derivative liability—230
Other non-current liabilities—31
Deferred tax liability6,0946,952
Total liabilities20,02919,564
Commitments and contingencies (Note 13)--
Shareholders’ equity:
Share capital of $0.000000005 par value
Authorized: 4,365,687,180,943 and 761,963,201,733 ordinary shares at June 30, 2026, and December 31, 2025; issued and outstanding: 140,032,769,533 and 90,536,879,533 ordinary shares at June 30, 2026, and December 31, 2025, respectively1—
Additional paid-in capital243,759234,318
Capital redemption reserve59,34259,342
Accumulated other comprehensive loss(695)(782)
Accumulated deficit(283,812)(264,550)
Total shareholders’ equity18,59528,328
Total liabilities and shareholders’ equity$38,624$47,892
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.